Techulon has signed a distribution agreement with Nacalai USA and its parent company Nacalai Tesque for its Glycofect Transfection Reagent platform products in Japan.
Subscribe to our email newsletter
Glycofect is designed to be particularly effective in primary cells of therapeutic interest and is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.
The Glycofect family of reagents has a biodegradable composition that provides for efficacious delivery with very low toxicity in key cell types.
Techulon president Frank Akers said they are pleased to have Nacalai represent Techulon in Japan and they look forward to expand their business in the market.
Nacalai Tesque is a manufacturer and distributor of life science and chemical research reagents in Japan.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.